Market revenue in 2023 | USD 67.0 million |
Market revenue in 2030 | USD 126.1 million |
Growth rate | 9.5% (CAGR from 2023 to 2030) |
Largest segment | Surgery |
Fastest growing segment | Intralesional injections |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Radiotherapy (RT), Intralesional injections, Intravenous Medications, Chemical peeling treatment, Surgery, Topical chemotherapy, Oral Medications |
Key market players worldwide | Bausch Health Companies Inc, Almirall SA, Genentech, Novartis AG ADR, Regeneron Pharmaceuticals Inc, Dr Reddy's Laboratories Ltd ADR, Taro Pharmaceuticals, Accord Healthcare |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to basal cell carcinoma treatment market will help companies and investors design strategic landscapes.
Surgery was the largest segment with a revenue share of 35.97% in 2023. Horizon Databook has segmented the Brazil basal cell carcinoma treatment market based on radiotherapy (rt), intralesional injections, intravenous medications, chemical peeling treatment, surgery, topical chemotherapy, oral medications covering the revenue growth of each sub-segment from 2018 to 2030.
Brazil has the largest population in Latin America. Skin cancer, including BCC, is the most common type of cancer in Brazil, accounting for 25% of all cancer cases. Recognizing the urgent need for reliable instrumentation for early detection of skin cancer, INESC P&D Brazil initiated a research line in this area.
Currently, skin cancer diagnosis relies on visual identification of anomalies, followed by surgical removal and biopsy to determine malignancy. INESC P&D Brazil aims to develop a noninvasive probe for real-time, in vivo diagnostics, which could revolutionize skin cancer detection in Brazil.
According to the International Agency for Research on Cancer, in 2022, NMSC prevalence reported in Brazil was 27,680.
Horizon Databook provides a detailed overview of country-level data and insights on the Brazil basal cell carcinoma treatment market , including forecasts for subscribers. This country databook contains high-level insights into Brazil basal cell carcinoma treatment market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account